Citations

Mayo Clinic

Clear

36 citation(s) found for "Toro-Tobon, David".

Artificial Intelligence Models to Predict Recurrence in Patients with Differentiated Thyroid Cancer: A PROBAST + AI Systematic Review of Clinical Applicability
Solis-Pazmino, Paola , Samaniego, Alison Fernanda , Laurini de Souza Meyer, Erika , Pilatuna, Eduardo A , González-Velázquez, Camilo , Lincango, Eddy P., Figueroa, Luis A , Toro-Tobon, David

Thyroid® | November 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10507256261504546 | PMID 43018984 Get It

Background: Differentiated thyroid cancer (DTC) generally carries an excellent prognosis, yet recurrence occurs in up to 8–9% of patients. Artificial intelligence (AI) models are increasingly proposed to predict DTC recurrence; however, their methodological quality and clinical readiness are poorly defined. We conducted a systematic review to evaluate the methodological quality, risk of bias, and applicability of these models using the PROBAST + AI framework. Methods: We searched Ovid MEDLINE, Embase, Cochrane databases, Scopus, and Web of Science from inception to July 13, 2026. Eligible studies included original research developing or validating AI models for recurrence in DTC. Model quality (for development), risk of bias (for evaluation), and applicability were assessed using the PROBAST + AI framework, with a focus on discrimination, calibration, and validation strategies (PROSPERO; registration number [CRD420251004644]). Results: Of 673 records screened, 34 studies were included (21 unique datasets and 13 UCI-derived publications), encompassing 21,267 patients with a recurrence rate of 7.8%. Most were developed in Asian cohorts (17 of 21 datasets) and were structured clinical/tabular variables (82.4%), including demographic, clinical, laboratory, and pathological data, whereas the remaining models incorporated multimodal inputs such as imaging-derived or radiomic features. Notably, nearly one quarter of included studies (13 of 34, 38%) represented reanalysis of a single dataset. Discrimination was reported in 22 of 34 studies (64.7%) (area under the receiver operating characteristic curve [AUC] 0.67–1.00), though only 10 studies assessed calibration, none with standardized metrics. The PROBAST + AI assessment revealed high overall quality concerns in 26 of 34 (76.5%) development studies due to reliance on single-center cohorts, inadequate handling of missing data, and absence of external validation. Only 6 of 34 included studies (17.6%) were judged to have low overall quality concern, whereas 17 of 34 (50.0%) were rated as having low applicability concern. Conclusions: AI models for predicting DTC recurrence show promising discriminatory performance but have substantial methodological shortcomings in development, and a lack of calibration and external validation necessary for clinical use. Given the guidelines’ emphasis on risk-adapted de-escalation of therapy, the development of robust, validated, and clinically calibrated AI tools is a priority. Current evidence remains insufficient to support routine clinical use.
Metastasis of Nonthyroidal Malignancies to the Thyroid Gland
Crespo-Trevino, Ricaurte , Choe, Justin, Hibbert, Rebecca , Toro-Tobón, David , Stan, Marius N. , Castro, M. Regina

American Journal of Clinical Oncology | November 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/coc.0000000000001386 | PMID 42980487 Get It

Objectives: Metastasis to the thyroid gland (MTT) is uncommon, and its presentation, diagnosis, and management remain incompletely characterized. We described a contemporary institutional cohort and examined detection, diagnostic evaluation, treatment, and survival after MTT diagnosis. Methods: We conducted a retrospective descriptive cohort study of patients with pathologically confirmed MTT who were evaluated at the Mayo Clinic in Rochester, Minnesota, from 2010 through 2025. Clinical, imaging, cytologic, pathologic, treatment, and outcome data were abstracted from the electronic health record. Survival was estimated using the Kaplan-Meier method. Results: Among 42 patients, the most common primary malignancies were kidney (40.5%) and lung (23.8%). MTT was detected incidentally on staging or surveillance imaging in 66.7% and was symptomatic in 23.8%. The median interval from primary cancer diagnosis to MTT was 3.67 years and was longer for kidney cancer (8.7 y) than lung cancer (0.94 y). Most lesions were unifocal (81.0%); common ultrasound features were solid composition (50.0%) and hypoechogenicity (47.6%), but findings were nonspecific. Among 23 patients evaluated with a single fine-needle aspiration (FNA) before diagnosis, metastasis was confirmed on the first procedure in 56.5% of cases. Eighteen patients underwent surgery. The median overall survival after MTT diagnosis was ∼1.75 years; outcomes differed by surgical status, although treatment selection and disease extent preclude causal interpretation. Conclusions: MTT should be considered in patients with a new thyroid lesion and a history of malignancy. Tissue diagnosis may require repeat FNA, core-needle biopsy, and immunohistochemistry. Management should be individualized based on symptoms, primary tumor biology, extent of systemic disease, and goals of care.
What Happens after an Incidental Thyroid Nodule? Patterns of Thyroid Ultrasound Use and Downstream Evaluation
Larios, Felipe , Vilatuna Andrango, Luis, Borras-Osorio, Mariana , Branda, Megan , Toro-Tobon, David , Cabezas, Esteban , Mateo Chavez, Maria, Claros, Ana Gabriela , Lizarazo Jimenez, Maria, Alzamora, Ivan Mateo , Gomez-Alvarez, Esteban , Al Zahidy, Misk , Fan, Jungwei W, Ponce, Oscar Josue

Thyroid® | September 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10507256261493769 | PMID 42813606 Get It

Background: Incidental thyroid nodules (ITNs) detected on nonthyroid imaging contribute to thyroid cancer overdiagnosis, largely through downstream evaluation initiated by thyroid ultrasound (TUS). However, TUS follow-up rates for ITNs and their drivers in routine practice remain unclear. We quantified TUS utilization after ITN detection and identified patient, imaging, nodule, and reporting factors associated with this first step in the diagnostic cascade. Methods: We conducted a retrospective cohort study of adults without prior thyroid disease who underwent imaging that incidentally captured the thyroid at Mayo Clinic sites (2017–2023). A validated natural language processing pipeline identified ITNs and extracted nodule characteristics from radiology reports across multiple imaging modalities. The main outcome was the rate of TUS within 180 days after ITN detection. Clinical outcomes, including thyroid biopsy, thyroidectomy, and thyroid cancer diagnosis, were compared between patients who underwent TUS and those who did not. Factors associated with TUS utilization were assessed using multivariable logistic regression with penalized variable selection. Results: Among 115,683 patients who underwent thyroid-capturing imaging, 8426 (7.3%) had an ITN. These patients were predominantly female (64.6%) and White (89.7%), with a mean age of 61.7 years (standard deviation 15.2). Most nodules were detected on computed tomography (80.8%), most commonly from chest imaging (52.3%). Overall, 1677 patients with ITNs (19.9%) underwent TUS. In multivariable analysis, TUS use was independently associated with higher body mass index (odds ratio [OR], 1.20 per 10-unit increase; confidence interval [CI] [1.08–1.33]), nodule size ≥1.5 cm (OR, 1.79; CI [1.52–2.10]), and a radiologist recommendation (OR, 2.51; CI [2.12–2.98]), whereas older age was associated with lower odds of TUS (OR, 0.89 per 10-year increase; CI [0.84–0.93]). Patients undergoing TUS had higher rates of thyroid biopsy, partial thyroidectomy, and total thyroidectomy compared with those without it. All detected thyroid cancers (103 cases) occurred in the TUS group, representing 6.1% of that cohort. Conclusions: One in five patients with ITNs underwent TUS, representing a critical gateway to downstream diagnostic procedures and thyroid cancer detection. Factors associated with TUS utilization highlight opportunities to better define appropriateness of ultrasound after incidental nodule detection and to reduce unnecessary testing and treatment.
The Artificial Intelligence “Goalkeeper”: Preventing Unnecessary Biopsies in the Era of Thyroid Cancer Overdiagnosis
Toro-Tobon, David, Toro-Tobón, David

Clinical Thyroidology® | August 19, 2026 | Volume: 38 | Issue: 1 | Pages: 32-35

10.1177/23299711261420467 Get It

From Pixels to Payer Savings: Balancing Accuracy and Health Care Costs with AI-Adapted Ultrasonography for Thyroid Nodules
Toro-Tobon, David, Toro-Tobón, David

Clinical Thyroidology® | July 13, 2026 | Volume: 38 | Issue: 7 | Pages: 259-263

10.1177/23299711261466446 Get It

Deprescribing Levothyroxine in Older Adults: Time to Challenge the “Lifelong” Dogma?
Toro-Tobon, David, Toro-Tobón, David

Clinical Thyroidology® | May 20, 2026 | Volume: 38 | Issue: 5 | Pages: 155-159

10.1177/23299711261448638 Get It

Clinician in the loop: a flawed solution for AI oversight
Toro-Tobon, David, Ponte, Oscar Ponce, Montori, Victor M, Brito, Juan P, Toro-Tobón, David , Montori, Victor , Brito, Juan P.

BMJ | May 5, 2026 | Volume: 393 | Issue: No issue available | Pages: e089213

10.1136/bmj-2025-089213 | PMID 42086290 Get It

Artificial intelligence-enabled analysis of radiology reports: epidemiology and outcomes of incidental thyroid findings
Larios, Felipe , Borras-Osorio, Mariana, Wu, Yuqi, Claros, Ana Gabriela, Toro-Tobon, David, Cabezas, Esteban , Loor-Torres, Ricardo, Chavez, Maria Mateo , Maldonado, Kerly Guevara, Andrango, Luis Vilatuna, Jiménez, María Camila , Alzamora, Ivan Mateo , Zahidy, Misk Al, Montero, Marcelo, Proano, Ana Cristina , Jacome, Cristian Soto , Ponce-Ponte, Oscar J, Larios, Felipe , Mateo Chavez, Maria, Guevara Maldonado, Kerly, Vilatuna Andrango, Luis, Lizarazo Jimenez, Maria, Al Zahidy, Misk, Fan, Jungwei W, Branda, Megan E. , Singh Ospina, Naykky , Brito, Juan P , Mateo Chavez, Maria B , Borras-Osorio, Mariana , Claros, Ana Gabriela , Toro-Tobón, David , Loor-Torres, Ricardo , Guevara, Kerly , Fan, Jungwei , Ponte, Oscar Ponce, Ospina, Naykky Singh , Brito, Juan P.

The Journal of Clinical Endocrinology & Metabolism | April 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1210/clinem/dgag186 | PMID 42037237 Get It

Abstract Context Incidental thyroid findings (ITFs) are increasingly detected on imaging performed for non-thyroid indications. Their prevalence, features, and consequences remain undefined. Objective To develop, validate, and deploy a natural language processing (NLP) pipeline to identify ITFs in radiology reports and assess their prevalence, features, and clinical outcomes. Design Retrospective cohort study. Setting Mayo Clinic sites (Rochester, Arizona, Florida, Mayo Clinic Health System). Participants Adults without prior thyroid disease undergoing thyroid-capturing imaging from July 1, 2017, to September 30, 2023. A transformer-based NLP pipeline identified ITFs and extracted nodule characteristics from image reports from multiple modalities and body regions. Outcomes ITF prevalence, downstream thyroid ultrasound, biopsy, thyroidectomy, and cancer diagnosis. Logistic regression identified demographic and imaging-related factors. Results Among 115 683 patients (mean age, 56.8 [SD 17.2]; 52.9% women), 9077 (7.8%) had an ITF (92.9% nodular). ITFs were more likely in women, older adults, higher BMI, and in imaging ordered by specialties different from Emergency Medicine. Compared with chest CT, ITFs were more likely via neck CT, PET, and nuclear medicine scans. Nodule characteristics were poorly documented, with size reported in 44% and other features in fewer than 15%. Compared with patients without ITFs, those with ITFs had higher odds of thyroid nodule diagnosis (OR 45, 95%CI 41.1-49.3), biopsy (OR 46.8, 95%CI 39.0-56.2) thyroidectomy (OR 55.8, 95%CI 31.3-99.3), and thyroid cancer diagnosis (OR 61.7, 95%CI 38.6-98.5). Most cancers were papillary (88.5%) and larger when detected after ITFs (2 cm SD 1.4) vs no ITF (1.3 cm SD 0.8). Conclusion ITFs were common and strongly associated with cascades leading to the detection of small, low-risk cancers, highlighting their role in overdiagnosis and the need for standardized reporting and more selective follow-up.
Beyond the Final Dose: The Chronic Glycemic Impact of Teprotumumab
Toro-Tobón, David

Clinical Thyroidology® | April 22, 2026 | Volume: 38 | Issue: 3 | Pages: 99-102

10.1177/23299711261436502 Get It

The prediction paradox: Artificial intelligence, genetics, and occult metastasis in thyroid cancer
Toro-Tobon, David , Toro-Tobón, David

The Journal of Clinical Endocrinology & Metabolism | February 13, 2026 | Volume: 111 | Issue: 9 | Pages: e2218-e2219

10.1210/clinem/dgag065 | PMID 41693145 Get It